diagnost tool
price close busi novemb
global leader diagnost breast
imag surgic product focu women
health also sell medic aesthet
look make tuck-in deal acceler
growth reiter hold lower pt
think holog ceo steve macmillan sum best earn call
said oper sever flat declin market lead market
share make challeng grow despit finish respect
y/i revenu growth adj ep growth certainli bad fall short
manag goal sustain mid-single-digit revenu growth manag
initi soft guid report revenu growth includ
revenu relat pend acquisit ssi overal good
collect asset would like see evid growth
think possibl upgrad stock reiter hold lower pt
revenu beat adj ep match our/street rev
rep fxn beat y/i /street
compar model deliv beat diagnost beat gyn
surgic beat blood screen beat breast health partial off-set
miss medic aesthet adj om miss
gross margin miss adj gm y/i miss due
higher manufactur cost stronger us dollar product mix annual hit
relat china tariif unclear us gm declin turn corner though
indic could expand
soft guid miss mark initi guidanc rev
rep fxn midpoint our/
street rep adj ep rep our/
street similarli guid rev our/ street
adj ep
soft guid includ revenue acquir ssi busi
breast remain bright spot breast rev
beat us led ou growth fxn rep growth us
set tomo quarterli placement record year us launch place
system us convers rate instal base
estim competit system us
upgrad newer acquisit faxitron ad
revenu also aid holx newer smartcurv paddl breast
stabil system perform dimens system
molecular diagnost remain strong total diagnost rev rep
fxn beat pace molecular diagnost revenu
rep fxn line compani cytolog
perinat segment rev came flat
medic aesthet cynosur rev continu miss estim rev
miss slightli beat street manag took anoth
impair charg cynosur time million manag commun
degre caution relat busi sale laser struggl
medic aesthet declin prior year comp
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
trim pt reduc pt use multipl
adj ep estim assum revenu ep
growth formerli pt use multipl adj ep estim
manag guid segment manag indic expect
low mid-single-digit revenu growth breast health gyn/surg diagnost
exclud blood screen busi manag guid blood screen
significantli manag guid medic
aesthet skelet busi grow slowli aforement
busi unit manag expect molecular diagnost grow either msd hsd
manag guid also includ expect revenu contribut
super sonic imagin expect close begin recogn revenu
spread across three quarter
manag guid assum chang share count despit fact
compani repurchas share buyback recent
year manag indic chang capit alloc strategi thu
despit guid dilut share outstand think
like end year dilut share outstand less
manag repurchas stock
respect invest tuck-in acquisit
manag indic compani grew instal base flagship panther
instrument system place unit
place us ou indic roughli inning
place flagship panther instrument us certainli earlier
manag indic averag annuiti revenu per panther instrument
grew high-singl digit cite hsd growth assay
includ ct/ng hpv trichomona indic see nice lift
growth gyn/surg busi mark fastest
growth rate quarter led primarili myosur evid
stabil novasur line also call contribut newer product line
like new omni hysteroscop
medic aesthet revenu grow y/i though easi comp
manag cite strength skin off-set struggl traction laser
manag leverag ratio came adj
ebitda came quarter grew y/i
hold unchang target price novemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price novemb
diagnost tool
hold unchang target price novemb
diagnost tool
